Metagenomi Inc (MGX)

Currency in USD
2.26
-0.04(-1.74%)
Real-time Data·
MGX Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 8 days
Fair Value
Day's Range
2.212.32
52 wk Range
1.234.92
Key Statistics
Prev. Close
2.3
Open
2.3
Day's Range
2.21-2.32
52 wk Range
1.23-4.92
Volume
198.09K
Average Volume (3m)
625.59K
1-Year Change
-36.64%
Book Value / Share
5.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.75
Upside
+375.66%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Metagenomi Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Metagenomi Inc Company Profile

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Compare MGX to Peers and Sector

Metrics to compare
MGX
Peers
Sector
Relationship
P/E Ratio
−1.1x−3.4x−0.5x
PEG Ratio
−0.01−0.190.00
Price/Book
0.4x2.5x2.6x
Price / LTM Sales
1.9x11.5x3.3x
Upside (Analyst Target)
334.8%112.6%43.5%
Fair Value Upside
Unlock1.7%6.3%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.75
(+375.66% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.68 / -0.75
Revenue / Forecast
4.12M / --
EPS Revisions
Last 90 days

MGX Income Statement

People Also Watch

32.94
BMNR
+5.81%
4.405
PRME
-2.11%
0.532
WINT
-8.56%
158.51
CRCL
-3.83%
51.710
ASTS
+0.64%

FAQ

What Stock Exchange Does Metagenomi Trade On?

Metagenomi is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Metagenomi?

The stock symbol for Metagenomi is "MGX."

What Is the Metagenomi Market Cap?

As of today, Metagenomi market cap is 85.98M.

What Is Metagenomi's Earnings Per Share (TTM)?

The Metagenomi EPS (TTM) is -2.11.

When Is the Next Metagenomi Earnings Date?

Metagenomi will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is MGX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Metagenomi Stock Split?

Metagenomi has split 0 times.

How Many Employees Does Metagenomi Have?

Metagenomi has 176 employees.

What is the current trading status of Metagenomi (MGX)?

As of 05 Aug 2025, Metagenomi (MGX) is trading at a price of 2.26, with a previous close of 2.30. The stock has fluctuated within a day range of 2.21 to 2.32, while its 52-week range spans from 1.23 to 4.92.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.